Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

5 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
5(100.0%)
5Total
Phase 4(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01086085Phase 4Completed

A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive

Role: collaborator

NCT01829685Phase 4Unknown

Efficacy Optimizing Extension Study of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy

Role: collaborator

NCT01529255Phase 4Unknown

EFFORT Extension Study

Role: collaborator

NCT01088009Phase 4Completed

Efficacy Optimizing Research of Lamivudine Therapy

Role: collaborator

NCT00962533Phase 4Completed

EFFicacy Optimization Research of Telbivudine Therapy

Role: collaborator

All 5 trials loaded